Park West Asset Management’s Novavax NVAX Stock Holding History

Park West Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,528,857	Closed	-$16.2M	–	52
2025 Q1	$16.2M	Buy	+2,528,857	New	+$20.9M	1.31%	30

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Park West Asset Management's NVAX Position: Q2 2025 in Review

Park West Asset Management sold out of Novavax (NVAX) in Q2 2025, closing a stake of 2,528,857 shares — an estimated $16.2M sold.

Park West Asset Management first reported a position in NVAX in Q1 2025 and held it in 1 quarter. The position peaked at $16.2M in Q1 2025. 251 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

Park West Asset Management reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
Park West Asset Management sold 2,528,857 Novavax shares in Q2 2025, an estimated $16.2M.
Park West Asset Management first reported a position in Novavax in Q1 2025 and held it in 1 quarter.
Park West Asset Management's Novavax position peaked at $16.2M in Q1 2025.
251 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on Park West Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.